Raredr

Emerging Therapies for Duchenne Muscular Dystrophy

Jean Mah, MD
Published Online: Friday, Nov 04, 2016



Jean L Mah, MD,  Associate Professor of Pediatric Neurology at Alberta Children's Hospital talks about the history, pathogenesis, treatment, and standard of care for boys with Duchenne muscular dystrophy. This symposium was filmed at the Child Neurology Society annual meeting in Vancouver, Canada on October 28, 2016.
 
Some of the therapies/targets discussed by Dr Mah include eteplirsen, SRP-053, NS-065, SRP-4045, DS-514b, ataluren, follistatin, AAV microdystrophin, GALGT2, myoblast transplant, cardiac stell cells, iPS stem cells, ezutrmid, domoagrozumab, BMS-986089, FG-3019, CAT-1004, givinostat, vamorolone, rimiporide, ARM210, nebivolol, spriromolactone, eplerenone, Ramipril, carvedilol, and idebenone. 
 
For more information about some of the clinical trials and therapies discussed by Dr Mah, visit jettfoundation.org.

Rare Disease Report would like to thank Dr Mah and the Jett Foundation for their support in allowing us to film this symposium and to share it with the rare disease community.

Latest Articles
eSight eyewear is the Star Trek like device that allows legally blind 13-year-old, Ethan LaCroix, the ability to play basketball with the Harlem Globetrotters
The 2017 Neuro Film Festival awarded William T. Doorley with the Neuroscience Is…™ Essential award for “Work in Progress: The Remarkable Journey of Dr. Warden.”
Brineura (cerliponase alfa) is an enzyme replacement therapy that in just a few short years has shown itself to be an effective treatment for children with CLN2 disease.
The 2017 Neuro Film Festival recently awarded Meghan Tucker with the Neuroscience Is…™ Critical award for her video, “BethAnn Telford World Marathon Challenge.”
$vacMongoViewPlus$ $vAR$